- Interim results demonstrate average reduction of 64% (p
Denali Therapeutics Announces Robust Reduction in Neurofilament Light (NfL) with DNL310 (ETV: IDS) Treatment in MPS II (Hunter Syndrome)
On 6ix: 6ix.com/news/denali-therapeutics-announces-robust-reduction-in-neurofilament-light-nfl-with-dnl310
Denali Therapeutics' next earnings callDenali Therapeutics (NASDAQ:DNLI) Q3 2026 Earnings Call · Nov 3, 2026 at 4:30 PM ESTRegister
Denali Therapeutics Inc. on 6ix
Story so far
- Denali Therapeutics Announces New Interim Data from Phase 1/2 Study of DNL310 (ETV: IDS) in MPS II (Hunter Syndrome) at SSIEM 2022
- Denali Therapeutics Announces Continued Progress in DNL310 (ETV: IDS) Program for MPS II (Hunter Syndrome) Supporting Planned Initiation of Phase 2/3 Clinical Trial
- Denali Therapeutics Announces Presentations on DNL310 (ETV: IDS) Development Program in MPS II (Hunter Syndrome) at the Upcoming WORLDSymposium™
Earlier from Denali Therapeutics
- Denali Therapeutics Reports First Quarter 2023 Financial Results and Business Highlights
- Biogen Exercises Option with Denali to Develop and Commercialize Antibody Transport Vehicle Program Targeting Amyloid Beta
- Denali Therapeutics Announces New DNL343 (eIF2B Agonist) Phase 1b Data in ALS To Be Presented at the Upcoming AAN Annual Meeting
- Denali Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Business Highlights
- Denali Therapeutics Announces New Interim Data from DNL310 Phase 1/2 Study for MPS II and DNL126 Preclinical Data for MPS IIIA at WORLDSymposium™
Later from Denali Therapeutics
- Flagship Pioneering Unveils Empress Therapeutics to Revolutionize Drug Discovery by Applying the Power of Genetics to Identify Small Molecule Drugs
- Denali Therapeutics Reports Second Quarter 2023 Financial Results and Business Highlights
- Denali Therapeutics Announces New Interim Data from Phase 1/2 Study of DNL310 (ETV: IDS) in MPS II (Hunter Syndrome) at SSIEM 2023
- Denali Therapeutics Reports Third Quarter 2023 Financial Results and Business Highlights
- Denali Therapeutics Announces Key Anticipated 2024 Milestones and Priorities to Further Advance Its Therapeutics Portfolio for Neurodegeneration and Lysosomal Storage Diseases
Follow Denali Therapeutics into a list and get an email when it puts out news.
Follow Denali Therapeutics